Critical Diagnostics
Critical Diagnostics is a privately held San Diego-based medical diagnostics company founded in 2004 that develops and commercializes novel biomarkers for cardiovascular disease, serving clinical and laboratory customers in the U.S. diagnostics market.
- Company typePrivate
- Founded2004
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Critical Diagnostics does
Critical Diagnostics is a privately held medical diagnostics company headquartered in San Diego, California, founded in 2004. The company is engaged in the research, development, and commercialization of novel biomarkers applied to cardiovascular disease, positioning it within the clinical diagnostics value chain where biomarker assays are ultimately deployed to inform disease detection, prognosis, or treatment decisions. Its core activity centers on biomarker R&D, with the company employing between 11 and 50 people.
The company's operating footprint is small and U.S.-based, with no disclosed international expansion, subsidiaries, or partnered commercial channels in the available data. Capital formation has been limited to two disclosed equity rounds — approximately $2.57M in March 2013 and $8.5M in January 2018 — bringing cumulative known funding to roughly $11.1M. Investors and lead participants are not disclosed for either round. Leadership comprises CEO Dennis Dalangin, President James Snider, and founders David M. Geliebter (co-founder & executive chairman) and Sven M. Jacobson (co-founder).
The company's business model, specific product portfolio, pricing structure, customer mix, regulatory clearances (e.g., FDA filings), and intellectual property estate are not detailed in the available inputs. There is no disclosed API, no published revenue, and no partnership or distribution data. Given these gaps, the commercial maturity and near-term scalability of Critical Diagnostics cannot be reliably assessed from the provided evidence.
Critical Diagnostics firmographics
Firmographics- Name
- Critical Diagnostics
- Website
- https://criticaldiagnostics.com
- Company type
- Private
- Founded year
- 2004
- Headcount range
- 11–50 employees
- Short description
- Critical Diagnostics is a privately held San Diego-based medical diagnostics company founded in 2004 that develops and commercializes novel biomarkers for cardiovascular disease, serving clinical and laboratory customers in the U.S. diagnostics market.
- Ownership category
- akta.pro rank
Critical Diagnostics industry classification
Industry- Product category
- Cardiovascular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where Critical Diagnostics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Critical Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Critical Diagnostics product offering
Product offeringCore offering
Critical Diagnostics is engaged in the research, development, and commercialization of novel biomarkers focused on cardiovascular diseases. The company translates biomarker discoveries into diagnostic products used to assess cardiac conditions for clinical and laboratory customers.
Product overview
Critical Diagnostics is a medical diagnostics company. The source content is limited to an article reference about medical diagnostics tests and imaging, without specific product details about Critical Diagnostics' offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel cardiovascular biomarkers
Companies that use Critical Diagnostics
Customer profileIdeal customer profiles1 record
Critical Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Critical Diagnostics partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
Critical Diagnostics competitors and assessment
Company assessmentDirect peers
- BG Medicine: BG Medicine developed galectin-3, a cardiovascular risk-stratification biomarker used in heart failure — directly comparable to Critical Diagnostics' cardiac biomarker focus and small-cap diagnostics profile.
Broad incumbents
- Abbott Diagnostics: Abbott markets widely adopted cardiac biomarker assays including troponin and BNP on its ARCHITECT and i-STAT platforms, dominating the same clinical category Critical Diagnostics targets.
- Roche Diagnostics: Roche's Elecsys cardiac menu (NT-proBNP, high-sensitivity troponin, Galectin-3) competes in the same cardiovascular biomarker segment and sets the reimbursement and guideline benchmarks Critical Diagnostics must meet.
- Siemens Healthineers (Diagnostics): Siemens offers the ADVIA Centaur and Atellica cardiac biomarker assays (NT-proBNP, troponin), making it a broad incumbent serving the same cardiology laboratories as Critical Diagnostics.
- Beckman Coulter Diagnostics: Beckman Coulter's Access family includes cardiac biomarker assays installed across hospital and reference labs, competing for the same clinician mindshare and lab budgets as Critical Diagnostics.
- Thermo Fisher Scientific (BRAHMS): Through the BRAHMS portfolio, Thermo Fisher markets procalcitonin and other specialty biomarker assays, and is an active acquirer of novel cardiac biomarkers — directly comparable as both a competitor and potential partner to Critical Diagnostics.
- QuidelOrtho: QuidelOrtho markets a broad menu of immunoassays including cardiac markers across its Vitros and Sofia platforms, placing it in the same diagnostics laboratories and hospitals targeted by Critical Diagnostics.
Emerging players
- Meso Scale Diagnostics: Meso Scale Diagnostics offers multiplexed assay platforms for biomarkers including cardiovascular disease markers, comparable to Critical Diagnostics in offering research and clinical-grade biomarker measurement.
- Singulex: Singulex developed high-sensitivity cardiac biomarker immunoassays (e.g., cTnI) — a comparable small-cap diagnostics company pursuing novel cardiovascular biomarkers, illustrating both the technical and competitive parallels.
- Myriad Genetics: Myriad has expanded into cardiovascular and specialty biomarker testing through its Vectra, Prolaris, and acquired diagnostics assets, operating as a specialty biomarker testing services company comparable in business model to a biomarker commercializer like Critical Diagnostics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Critical Diagnostics social profiles
Digital presenceCritical Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Critical Diagnostics leadership team
Management profileNumber of profiles
Profiles4 records
Critical Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Critical Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Critical Diagnostics
What does Critical Diagnostics do?
Critical Diagnostics is engaged in the research, development, and commercialization of novel biomarkers focused on cardiovascular diseases. The company translates biomarker discoveries into diagnostic products used to assess cardiac conditions for clinical and laboratory customers.
When was Critical Diagnostics founded?
Critical Diagnostics was founded in 2004. It employs 11 to 50 people.
Where is Critical Diagnostics based?
Critical Diagnostics is headquartered in San Diego, United States, in the North America region.
Who are Critical Diagnostics's main competitors?
BG Medicine is listed as a direct peer. Broad incumbents are Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers (Diagnostics), Beckman Coulter Diagnostics, Thermo Fisher Scientific (BRAHMS) and QuidelOrtho. Emerging players are Meso Scale Diagnostics, Singulex and Myriad Genetics.
Does Critical Diagnostics have an API?
No public API is recorded for Critical Diagnostics.
What industry is Critical Diagnostics in?
Critical Diagnostics's product category is Cardiovascular Diagnostics. Its primary akta.pro industry code is HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk). Its NAICS code is 325413 and its SIC code is 2835.